BioCentury
ARTICLE | Emerging Company Profile

Edgewise: breaking away from dystrophin for muscular dystrophy

Edgewise emerges from stealth with $50M series B, dystrophin-independent muscle-stabilizing compounds

September 26, 2019 9:45 PM UTC
Updated on Nov 6, 2019 at 4:28 AM UTC

With a lead compound that staves off use-induced muscle damage, Edgewise thinks it can compete with dystrophin replacement therapies for muscular dystrophy.

Edgewise Therapeutics emerged from stealth this month with a $50 million series B round co-led by Novo Holdings A/S and U.S. Venture Partners and a portfolio of internally developed small molecule therapies for musculoskeletal indications including Duchenne and Becker muscular dystrophy. ...